Banner - Collaborative Care Symposium
News
All NewsContributorsMoney Matters
Media
All VideosExpert InterviewsMedical World NewsPodcastsBeyond The WallsCase Based Roundtable SeriesCase of the QuarterEyeViewGrand RoundsInsightsRapid ReadoutViewpointsWhat’s Your WhEYE?
Conferences
Conference CoverageConference Listing
Events
More
Publications
Digital EditionEurope Ophthalmology TimesModern RetinaSupplements and Featured Publications
CME
Partners
Resources
Job BoardSponsored

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Publications
  • CME
  • Partners
  • Subscribe
  • Resources
  • AMD
  • Biosimilars
  • COVID-19
  • Cataract
    • Cataract Surgery
  • Cataract Therapeutics
  • Clinical Diagnosis
    • The Residency Report
    • iOpeners
    • NeuroOp Guru
  • Cornea
  • DME
  • Dry Eye
    • Dry Eye Awareness
  • Gene Therapy
  • Geographic Atrophy
  • IOL
    • IOL Advances
  • Imaging
  • Interventional Glaucoma
    • Glaucoma Awareness
    • Glaucoma Insights
    • Therapeutic Glaucoma
  • OCT
  • Ocular Allergy
  • Ocular Surface Disease
  • Optic Relief
  • Optometry
  • Pediatrics
  • Pharmacy
  • Practice Management
    • Indispensable
  • Presbyopia
  • Ptosis
  • Refractive
    • Refractive Surgery
  • Retina
  • Surgery
  • Technology
  • Therapeutics
  • Understanding Antibiotic Resistance
  • Workplace
Spotlight -
Retina
Advertisement

Jogin Desai

Advertisement

Articles by Jogin Desai

Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.

ARVO 2025: Dr. Jogin Desai provides Phase 2 updates from a first-in-human RPE cell suspension trial

ByMartin David Harp,Hattie Hayes,Jogin Desai
May 6th 2025

The trial will assess allogeneic retinal pigment epithelium cells in the treatment of geographic atrophy.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

    1

    Optigo: Lead anti-VEGF program advancing toward IND-enabling studies

    2

    AAO 2025: Advancements in laser refractive surgery

    3

    Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5

    4

    From then to next: Five decades of transformation in ophthalmology

    5

    AAO 2025: A study of retinal vasculitis events with intravitreal agents

    • About
    • Advertise
    • Privacy
    • Editorial Info
    • Editorial Board
    • Terms and Conditions
    • Contact Us
    • Do Not Sell My Personal Information
    • Job Board
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    609-716-7777

    • Ophthalmology Times
    • Modern Retina
    • Optometry Times
    • Ophthalmology Times Europe
    EyeCare Network
    Brand Logo

    © 2025 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us